Premium
Distribution of human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes over the last decades
Author(s) -
Chan Paul K.S.,
Ho Wendy C.S.,
Yu MeiYung,
Pong WaiMei,
Chan Alexander C.L.,
Chan Amanda K.C.,
Cheung TakHong,
Wong Martin C.S.,
To KaFai,
Ng HoKeung
Publication year - 2009
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.24495
Subject(s) - adenosquamous carcinoma , medicine , human papillomavirus , carcinoma , cervical cancer , cervical carcinoma , hpv vaccines , basal cell , oncology , gynecology , hpv infection , cancer , adenocarcinoma
Human papillomavirus (HPV) type distribution among cervical cancers and its possible changes over time are key issues that determine the cost‐effectiveness of HPV vaccines. Cervical cancers diagnosed during 3 periods (1997–2007, N = 280; 1984–1986, N = 74; 1972–1973, N = 81) in Hong Kong were examined for HPV type distribution using sensitive broad‐catching methods. The results showed a variation in HPV distribution between histological groups. Among cervical squamous cell carcinoma (SCC) cases diagnosed over the past 10 years, HPV16 was most commonly found (61.2%), followed by HPV18 (17.7%), HPV52 (14.7%) and HPV58 (9.9%), whereas adeno/adenosquamous cell carcinoma was dominated by HPV18 (56.3%) and HPV16 (50.0%). The proportion of HPV16‐positive SCC showed a significant linear trend of increase with time (45.2% for 1972–1973, 58.8% for 1984–1986, 61.2% for 1997–2007; p Trend = 0.023), whereas HPV52‐positive SCC decreased with time (30.1% for 1972–1973; 29.4% for 1984–1986, 14.7% for 1997–2007; p Trend = 0.001). Vaccines comprising HPV16/18 cover 62.6% of SCC and 93.8% of adeno/adenosquamous carcinoma in Hong Kong, and inclusion of HPV52 and HPV58 can increase the coverage by 18.4% for SCC and 4.1% for adeno/adenosquamous cell carcinoma. HPV type distribution may change over time. Further investigations to reveal the determinants for such changes and continuous monitoring for possible type replacement as a result of widespread long‐term use of HPV vaccines are warranted. Multiple infections are commonly revealed by sensitive broad‐catching methods such as those used in this study. However, their implication on vaccine efficacy and cost‐effective analyses should be taken cautiously. © 2009 UICC